| 1. |
New HIV treatment evidence challenges widely-held theory |
| |
PharmacoEconomics & Outcomes News Weekly,
Volume &NA;,
Issue 428,
2003,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 2. |
Enfuvirtide: cost and QOL effect in HIV infections |
| |
PharmacoEconomics & Outcomes News Weekly,
Volume &NA;,
Issue 428,
2003,
Page 3-4
K Salmon,
Preview
|
|
摘要:
Enfuvirtide is the first drug in a new class of antiretroviral agents known as HIV-1 fusion inhibitors. The addition of enfuvirtide to an optimised background regimen in treatment-experienced patients with HIV-1 infections has been found in two large pivotal phase III trials to significantly decrease plasma viral load and significantly increase CD4+ cell count at 24 weeks. However, enfuvirtide is a costly drug and works best in conjunction with other active drugs, thus its cost effectiveness is a salient issue in the HIV infections treatment arena. In addition, as enfuvirtide requires twice-daily injections and often causes painful injection-site reactions which persist throughout therapy, its impact on patients' health-related QOL (HRQOL) is of great interest to physicians and patients alike. These issues were examined in studies which were presented at poster sessions during the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment [Paris, France; July 2003].
ISSN:1173-5503
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 3. |
UK NICE issues guidance on somatropin, thiazolidinediones |
| |
PharmacoEconomics & Outcomes News Weekly,
Volume &NA;,
Issue 428,
2003,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 4. |
Pneumococcal infections prophylaxis suboptimal in sickle cell anaemia |
| |
PharmacoEconomics & Outcomes News Weekly,
Volume &NA;,
Issue 428,
2003,
Page 5-5
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 5. |
Factors predicting high resource use in borderline personality disorders |
| |
PharmacoEconomics & Outcomes News Weekly,
Volume &NA;,
Issue 428,
2003,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 6. |
Lower costs with celecoxib vs diclofenac plus omeprazole in arthritis |
| |
PharmacoEconomics & Outcomes News Weekly,
Volume &NA;,
Issue 428,
2003,
Page 7-7
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 7. |
A systematic programme implemented by a multidisciplinary team is a"cost-effective strategy for optimizing antibiotic use"in a hospital setting, |
| |
PharmacoEconomics & Outcomes News Weekly,
Volume &NA;,
Issue 428,
2003,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 8. |
GPs struggle to meet UK stroke prevention targets |
| |
PharmacoEconomics & Outcomes News Weekly,
Volume &NA;,
Issue 428,
2003,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 9. |
Dutasteride improves QOL in benign prostatic hyperplasia |
| |
PharmacoEconomics & Outcomes News Weekly,
Volume &NA;,
Issue 428,
2003,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 10. |
Eli Lilly and Company has joined the Pharmacy Care Alliance in the US in an effort to educate more low-income seniors about the LillyAnswers Card, |
| |
PharmacoEconomics & Outcomes News Weekly,
Volume &NA;,
Issue 428,
2003,
Page 11-11
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2003
数据来源: ADIS
|
首页
